This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic lymphocytic leukemia (CLL); non-Hodgkin's lymphoma (NHL)	SET nuclear oncogene (SET)	<p>Mouse and patient studies suggest inhibiting SET could help treat B cell CLL and NHL. In CLL patients, increased SET levels correlated with disease progression and low survival. In a mouse xenograft model of NHL, the SET antagonist peptide OP499 decreased tumor growth compared with vehicle. Next steps include additional preclinical studies to move OP499 into clinical trials for hematologic malignancies. OP449, a SET inhibitor from Oncotide Pharmaceuticals Inc., is in preclinical development for CLL and solid tumors.</p> <p>SciBX 4(34); doi:10.1038/scibx.2011.958 Published online Sept. 1, 2011</p>	Patent application filed covering use of OP499 in cancer and inflammation; available for licensing	<p>Christensen, D.J. <i>et al. Blood</i>; published online Aug. 15, 2011; doi:10.1182/blood-2011-04-351072</p> <p>Contact: Dale J. Christensen, Oncotide Pharmaceuticals Inc., Research Triangle Park, N.C. e-mail: dchristensen@oncotide.com</p>